Leiomyosarcoma future or investigational therapies

Following are some recently approved drugs in the treatment of the leimyosarcoma.

• Trabectedin was approved as a chemotherapy for leiomyosarcoma that cannot be operated or for the patients that previously underwent treatment with anthracycline. Trabectedin exerts its chemotherapeutic effect by alkylation and damages the DNA of cells, which prevents them from dividing, and causes them to die.
• Pazopanib, an oral therapy for advanced leiomyosarcoma, is often combined with chemotherapy and/or radiation therapy.It works as a potent and selective multi-targeted receptor tyrosine kinase inhibitor that blocks tumour growth and inhibits angiogenesis.
• Recently, Eribulin demonstrated an overall survival (OS) advantage in liposarcoma and leiomyosarcoma in a randomised Phase III clinical trial. In this manuscript, an overview of the efficacy and safety of eribulin in soft tissue sarcoma is presented, highlighting different clinical outcomes between histological subtypes and comparing data with other effective drugs used in the treatment of sarcomas. Eribulin works as a potent microtubule-destabilizing anticancer agent, which has other antitumor biological effects.Eribulin is highly effective in some STS populations and also has an acceptable toxicity profile.
• Currently, there are many investigational studies are going on to identify other agents that may prove useful in the treatment of Leiomyosarcoma.Clinical trials are testing new drugs to see if they're safe and if they work.

References

Template:WikiDoc Sources